A team of Japanese scientists has revealed a mechanism associated with an increased risk of behavioural defects among offspring of older fathers in a mouse study, with strong indications similar processes are involved in humans.
EMBO publicly launches the Early Evidence Base site, an experimental platform that blends human scientific expertise with artificial intelligence (AI) to highlight scientific findings posted in preprints. Preprints are manuscripts that are publicly shared online by researchers before formal publication in a peer-reviewed journal.
Molecular markers in the blood shown to be predictive of severe COVID-19 outcomes resulting from SARS-CoV-2 coronavirus infection have been identified in a study by a Chinese research team. The study results extend understanding of the pathophysiology and clinical progress of COVID-19 with potential for identifying early during the course of infection which individuals are most at risk of developing severe conditions and requiring hospital care.
EMBO congratulates nine life scientists on their selection as EMBO Global Investigators. They form the second cohort of the Global Investigator Network that was launched in 2019 and will start their four-year tenure in January 2021. The new Global Investigators will receive financial support for several networking, collaboration and training activities.
EMBO is pleased to announce that thirty life scientists have been selected as EMBO Young Investigators. They will join the existing network of 73 current and 384 former members of the programme. The new EMBO Young Investigators will receive financial and practical support for a period of four years, starting in January 2021.
This year’s EMBO Gold Medal is going to two researchers who study cell metabolism, Sarah-Maria Fendt and Markus Ralser.
New research published yesterday in The EMBO Journal reports that the SARS-CoV-2 coronavirus can target human neurons with the potential to cause disease of the central nervous system (CNS). The research showed that the virus can enter tiny laboratory-developed 3D structures called brain organoids that replicate key aspects of the human brain and induce pathological effects similar to early stages of diseases of the CNS such as Alzheimer’s.
Antibodies targeting the normal PrP version of the prion protein have been found in humans selected at random with no history of any associated transmissible spongiform encephalopathies.
EMBO has bestowed upon 63 leading scientists the lifetime honour of EMBO Membership in recognition of their remarkable achievements in the life sciences, it was announced today.
EMBO announces an extension of its current Short-Term Fellowship scheme: Core Facility Fellowships. These fellowships will support exchanges of technology and expertise between core research facilities that provide services to research institutions or universities.
